PURPOSE: We examined temporal trends in skeletal related events and associated charges in patients with renal cell carcinoma metastatic to bone.
We also identified patient and hospital characteristics associated with skeletal related events and related mortality.
MATERIALS AND METHODS: Using the Nationwide Inpatient Sample we abstracted data on patients with renal cell carcinoma who were diagnosed with concomitant bone metastasis between 1998 and 2010. Patients who experienced a skeletal related event were identified and hospital charges were calculated. Multivariate regression models fitted with generalized estimating equations were used to examine predictors of skeletal related events and related in-hospital mortality.
RESULTS: Between 1998 and 2010 a weighted estimate of 144,889 renal cell carcinoma hospital visits of patients with bone metastasis was identified in the Nationwide Inpatient Sample, of which 20.8% involved a skeletal related event. In these cases from 1998 to 2010 the inflation adjusted mean yearly costs associated with hospital admission increased by 207% in 2013 United States dollars (estimated annual percent change 8.94%, p < 0.001). Conversely, the rates of skeletal related events and skeletal related event associated mortality decreased significantly (estimated annual percent change -1.11% and -2.9%, respectively, each p < 0.001).
CONCLUSIONS: The prevalence and in-hospital mortality of skeletal related event associated hospitalization for metastatic renal cell carcinoma is decreasing but such charges to health care in the United States are increasing at an alarming rate. These findings highlight the need for cost-effective treatment strategies to prevent or treat these morbid complications.
Written by:
Antczak C, Trinh VQ, Sood A, Ravi P, Roghmann F, Trudeau V, Chang SL, Karakiewicz PI, Kibel AS, Krishna N, Nguyen PL, Saad F, Sammon JD, Sukumar S, Zorn KC, Sun M, Trinh QD. Are you the author?
Cancer Prognostics and Health Outcomes Unit and Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan; Department of Urology, Ruhr University Bochum, Marienhospital, Herne, Germany; Division of Urologic Surgery and Center for Surgery and Public Health and Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Urology, University of Minnesota, Minneapolis, Minnesota.
Reference: J Urol. 2013 Dec 30. pii: S0022-5347(13)06209-5.
doi: 10.1016/j.juro.2013.12.042
PubMed Abstract
PMID: 24384157
UroToday.com Renal Cancer Section
